CD8A and neoplasm: KRAS mutation increase glycolysis metabolism, oxidative phosphorylation, and hypoxia pathway activation, promoting tumor development and restricting CD8+PD-1−T infiltration, thereby suppressing the anti-tumor immune response [19].